1. Home
  2. BSVN vs CLLS Comparison

BSVN vs CLLS Comparison

Compare BSVN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

N/A

Current Price

$45.40

Market Cap

393.6M

Sector

Finance

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$3.59

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BSVN
CLLS
Founded
2004
1999
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.6M
438.4M
IPO Year
2018
2007

Fundamental Metrics

Financial Performance
Metric
BSVN
CLLS
Price
$45.40
$3.59
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$53.33
$8.50
AVG Volume (30 Days)
13.6K
41.5K
Earning Date
01-15-2026
03-12-2026
Dividend Yield
2.37%
N/A
EPS Growth
N/A
N/A
EPS
4.50
N/A
Revenue
$95,676,000.00
$82,551,000.00
Revenue This Year
$4.59
$32.58
Revenue Next Year
$7.19
$20.68
P/E Ratio
$10.15
N/A
Revenue Growth
N/A
129.04
52 Week Low
$32.49
$1.10
52 Week High
$50.10
$5.48

Technical Indicators

Market Signals
Indicator
BSVN
CLLS
Relative Strength Index (RSI) 67.33 35.84
Support Level $43.03 $3.53
Resistance Level $44.31 $3.95
Average True Range (ATR) 0.98 0.19
MACD 0.22 -0.06
Stochastic Oscillator 100.00 11.40

Price Performance

Historical Comparison
BSVN
CLLS

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: